Keros Therapeutics, Inc. (KROS) intrinsic value & 10-year financials
Keros Therapeutics, Inc. (KROS) has a Graham intrinsic value of $76.40 per share. At $10.66 on Oct 17, 2026, the stock trades 86% below that value. Over the last 8 fiscal years revenue grew 70.3% a year to $244.1M, with an average return on invested capital of -546.5%.
- Graham intrinsic value
- $76.40
- Share price (Oct 17, 2026)
- $10.66
- Price vs Graham value
- 86% below
- Market cap
- $403.6M
- Revenue (FY2025)
- $244.1M
- Revenue growth (8-yr CAGR)
- 70.3%
- ROIC (10-yr avg)
- -546.5%
- Free cash flow (FY2025)
- $106.0M
KROS 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $244.1M | $87.0M | $2.30 | $106.0M | 27.7% | 218.0% |
| FY2024 | $3.5M | -$187.4M | -$5.00 | -$162.8M | -5939.0% | -980.4% |
| FY2023 | $151.0K | -$153.0M | -$5.20 | -$127.0M | -112543.7% | -1323.0% |
| FY2022 | $0 | -$104.7M | -$4.15 | -$71.3M | — | -935.2% |
| FY2021 | $20.1M | -$58.7M | -$2.52 | -$63.2M | -280.5% | -1164.3% |
| FY2020 | $0 | -$45.4M | -$2.93 | -$37.2M | — | 317.9% |
| FY2019 | $10.0M | -$12.3M | — | -$16.3M | -105.6% | 41.3% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Keros Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Keros Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just 0.4% ROIC.
Keros Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Keros Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $76.40 per share.